SUFU COE

REVIEW UroToday

SUFU COE

Search

Adult Neurogenic Lower Urinary Tract Dysfunction - David Ginsberg Details Diane Newman and David Ginsberg discuss the key recommendations of the AUA/SUFU guidelines on adult neurogenic lower urinary tract dysfunction, diagnosis, and evaluation. Dr. Ginsberg gives a deep background on neurogenic bladder and some of the challenges that tend to arise when treating these patients. They also discuss the quality of life for patients who are living with adult neurogenic lower...
The Effects of Vibegron on Ambulatory Blood Pressure in Patients With Overactive Bladder - Michael A. Weber Details Diane Newman is joined by Michael Weber discussing a novel medication for the treatment of overactive bladder and a study Dr Weber presented at the AUA 2021 Annual Meeting. Vibegron, a beta-3 receptor agonist is used for the treatment of overactive bladder. Adults with overactive bladder in the age range, 40 to 75, were randomized to treatment either with Vibegron 75 milligrams per day or placebo....
The OAB Clinical Care Pathway Mobile APP - Stephen Kraus Details In this informational video presentation, Stephen Kraus provides an update on the SUFU overactive bladder (OAB) Clinical Care Pathway as a dissemination effort to broadcast the advantages of the pathway for both physicians and patients. This initiative offers a comprehensive and evidence-based approach to the management of overactive bladder focused for the healthcare provider. After trial and err...
The Role and Timing of Urodynamics and Certificate in Urodynamics Virtual Course - Hashim Hashim Details Professor Hashim Hashim joins Diane Newman for a conversation on the definitions of lower urinary tract dysfunction and the role and timing of urodynamics in the diagnosis of the specific condition. They also share the learning objectives of the Certificate in Urodynamics Course, its intended audience, the history, and the benefits of the course. Professor Hashim is a world-renowned functional uro...
GEMTESA® (vibegron) for the Treatment of Patients with Overactive Bladder FDA Approved - Scott A. MacDiarmid Details Joining Diane Newman on UroToday's Bladder Health Center of Excellence is Scott MacDiarmid to discuss the United States Federal Drug Administration (FDA) approval of beta-3 agonist, GEMTESA® (vibegron), for the treatment of overactive bladder (OAB). This approval marks the first new oral branded OAB medication approved by the FDA since 2012. Biographies: Scott A. MacDiarmid, MD is director of the...